Work

FOS+ B cells: Key mediators of immunotherapy resistance in diverse cancer types

Year: 2024

Type: article

Abstract: B cells as important players in immunotherapy resistance, providing a novel biomarker for predicting treatment response. This study not only deepens our understanding of the immunological landscape influencing immunotherapy efficacy but also opens avenues for targeted interventions to overcome resistance.

Source: Molecular Therapy Oncology

DOI: 10.1016/j.omton.2024.200895

Authors: Xiangyang Zhang, Jiayao Ma, Yihong Chen, Xiangying Deng, Yan Zhang, Ying Han, Jun Tan, Gongping Deng, Yanhong Ouyang, Yulai Zhou, Changjing Cai, Shan Zeng, Hong Shen

Institutions: Central South University, City University of Hong Kong, Xiangya Hospital Central South University, Hunan Normal University, Yueyang Second People's Hospital, Hainan General Hospital, Hainan Medical University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900

Funders: National Natural Science Foundation of China, Central South University, China Postdoctoral Science Foundation, Natural Science Foundation of Fujian Province, Natural Science Foundation of Hunan Province, Key Research and Development Project of Hainan Province, Science and Technology Program of Hunan Province, Xiangya Hospital, Central South University, Fundamental Research Funds for the Central Universities, Fundamental Research Funds for Central Universities of the Central South University

Awards: G1211518762, G1977740159, G2171166193, G2514719296, G2933548003, G336511282, G3910932556, G5217273760, G5700981909, G6203891815, G6463213449, G7212968922, G7543527923, G7718612627, G8595253010

OpenAlex ID: W4403527720

FWCI: 0.764

Cites: 48

Cited by: 5

Related to: 10